Profile data is unavailable for this security.
About the company
Intuitive Surgical, Inc. develops, manufactures, and markets the da Vinci surgical system and the Ion endoluminal system. The Company's products and related services enable physicians and healthcare providers to access minimally invasive care. The da Vinci surgical system consists of a surgeon console or consoles, a patient-side cart, and a high-performance vision system. The da Vinci products fall into five categories, namely da Vinci surgical systems, da Vinci instruments and accessories, da Vinci Stapling, da Vinci Energy, and da Vinci Vision, including Firefly Fluorescence imaging systems and da Vinci Endoscopes. It also provides a comprehensive suite of systems, learning, and services offerings. The Ion endoluminal system consists of a system cart, a controller, a catheter, and a vision probe. It extends its commercial offerings beyond surgery into diagnostic procedures, enabling minimally invasive biopsies in the lung. Both systems use software, instruments, and accessories.
- Revenue in USD (TTM)7.87bn
- Net income in USD2.24bn
- Incorporated1995
- Employees13.68k
- LocationIntuitive Surgical Inc1020 Kifer RoadSUNNYVALE 94086United StatesUSA
- Phone+1 (408) 523-2100
- Fax+1 (408) 523-1390
- Websitehttps://www.intuitivesurgical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Edwards Lifesciences Corp | 5.62bn | 1.43bn | 41.51bn | 19.80k | 29.72 | 4.35 | 26.57 | 7.38 | 2.37 | 6.93 | 9.32 | 16.18 | 0.5032 | 1.12 | 7.72 | 283,904.00 | 12.76 | 16.63 | 14.98 | 19.12 | 78.63 | 76.71 | 25.35 | 24.84 | 2.89 | -- | 0.0585 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
| Cencora Inc | 293.96bn | 1.51bn | 48.41bn | 42.00k | 32.73 | 61.54 | 18.37 | 0.1647 | 7.51 | 7.51 | 1,467.70 | 3.99 | 4.53 | 15.59 | 12.44 | -- | 2.34 | 1.12 | 11.51 | 4.83 | 3.35 | 3.25 | 0.5168 | 0.2556 | 0.5291 | 19.37 | 0.848 | 65.38 | 12.12 | 10.36 | -13.53 | 13.02 | 9.45 | 4.98 |
| Becton Dickinson and Co | 20.18bn | 1.73bn | 65.16bn | 73.00k | 37.95 | 2.51 | 16.24 | 3.23 | 5.94 | 5.94 | 69.42 | 89.64 | 0.3667 | 3.10 | 7.25 | -- | 3.14 | 2.55 | 3.66 | 2.93 | 45.36 | 45.29 | 8.56 | 7.31 | 0.7405 | 9.56 | 0.437 | 76.96 | 4.16 | 3.14 | 17.41 | 10.83 | -5.40 | 4.29 |
| Medtronic PLC | 33.00bn | 4.29bn | 108.68bn | 95.00k | 25.86 | 2.24 | 15.61 | 3.29 | 3.28 | 3.28 | 25.19 | 37.81 | 0.3664 | 2.03 | 5.41 | 347,326.30 | 4.80 | 4.57 | 5.47 | 5.14 | 65.46 | 66.75 | 13.10 | 13.49 | 1.39 | 9.82 | 0.3677 | 80.58 | 3.64 | 1.16 | -2.18 | -4.56 | 6.95 | 6.65 |
| Boston Scientific Corporation | 15.91bn | 1.79bn | 134.86bn | 48.00k | 75.64 | 6.51 | 44.61 | 8.48 | 1.21 | 1.21 | 10.73 | 14.05 | 0.4412 | 1.91 | 6.91 | 331,458.30 | 4.96 | 2.50 | 5.85 | 2.91 | 69.09 | 68.84 | 11.24 | 6.47 | 1.02 | 6.02 | 0.3419 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
| Stryker Corp | 21.97bn | 3.59bn | 148.73bn | 52.00k | 41.82 | 7.38 | 32.15 | 6.77 | 9.33 | 9.33 | 57.08 | 52.86 | 0.5368 | 1.56 | 6.27 | 422,576.90 | 8.77 | 6.60 | 10.76 | 7.84 | 63.88 | 63.99 | 16.34 | 13.13 | 1.22 | -- | 0.4345 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
| Danaher Corp | 23.74bn | 3.93bn | 169.77bn | 61.00k | 44.35 | 3.31 | 27.45 | 7.15 | 5.30 | 5.24 | 32.05 | 71.03 | 0.2821 | 3.39 | 6.11 | 389,213.10 | 4.67 | 5.93 | 5.19 | 6.56 | 59.26 | 58.79 | 16.57 | 19.11 | 1.01 | 21.31 | 0.2546 | 14.33 | -10.33 | 6.98 | -32.50 | 11.85 | 16.10 | 11.32 |
| Intuitive Surgical, Inc. | 7.87bn | 2.24bn | 196.12bn | 13.68k | 88.51 | 12.59 | 71.11 | 24.93 | 6.22 | 6.22 | 21.81 | 43.75 | 0.4848 | 1.98 | 7.44 | 575,234.00 | 13.93 | 12.42 | 15.63 | 13.83 | 66.98 | 67.60 | 28.73 | 26.31 | 3.42 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
| Thermo Fisher Scientific Inc | 42.37bn | 6.14bn | 197.41bn | 122.00k | 32.37 | 4.03 | 21.00 | 4.66 | 15.95 | 15.95 | 110.12 | 128.08 | 0.4292 | 4.63 | 4.32 | 347,295.10 | 6.28 | 7.79 | 7.36 | 9.11 | 40.77 | 44.94 | 14.62 | 16.76 | 1.26 | 24.08 | 0.4183 | 6.75 | -4.58 | 11.96 | -13.74 | 14.43 | 14.30 | 15.39 |
| Abbott Laboratories | 41.22bn | 5.77bn | 203.38bn | 114.00k | 35.55 | 5.11 | 22.62 | 4.93 | 3.30 | 3.30 | 23.57 | 22.94 | 0.5629 | 2.71 | 6.08 | 361,552.60 | 7.88 | 7.72 | 9.77 | 9.39 | 55.81 | 56.73 | 13.99 | 14.39 | 1.14 | 28.44 | 0.2723 | 54.95 | -8.12 | 5.58 | -17.45 | 18.36 | 9.57 | 12.74 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 30.24m | 8.49% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 18.08m | 5.08% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 15.05m | 4.23% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 14.09m | 3.96% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 9.91m | 2.78% |
| Geode Capital Management LLCas of 30 Sep 2024 | 7.51m | 2.11% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 7.41m | 2.08% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 7.08m | 1.99% |
| Fisher Asset Management LLCas of 30 Sep 2024 | 4.78m | 1.34% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 4.41m | 1.24% |
